AR106138A1 - Compuestos y métodos para inhibir jak - Google Patents
Compuestos y métodos para inhibir jakInfo
- Publication number
- AR106138A1 AR106138A1 ARP160102919A ARP160102919A AR106138A1 AR 106138 A1 AR106138 A1 AR 106138A1 AR P160102919 A ARP160102919 A AR P160102919A AR P160102919 A ARP160102919 A AR P160102919A AR 106138 A1 AR106138 A1 AR 106138A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- compounds
- methods
- ethyl
- inhibit jak
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), en donde R¹ es metilo o etilo; R² se selecciona de metilo, etilo, metoxilo y etoxilo; R³ se selecciona de hidrógeno, cloro, flúor, bromo y metilo; R⁴ se selecciona de metilo, etilo y -CH₂OCH₃; R⁵ y R⁶ son cada uno individualmente metilo o hidrógeno; y R⁷ se selecciona de metilo, etilo, -(CH₂)₂OH y -(CH₂)₂OCH₃; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232629P | 2015-09-25 | 2015-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106138A1 true AR106138A1 (es) | 2017-12-13 |
Family
ID=56979589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102919A AR106138A1 (es) | 2015-09-25 | 2016-09-23 | Compuestos y métodos para inhibir jak |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9714236B2 (es) |
| EP (2) | EP3353168B1 (es) |
| JP (1) | JP6767491B2 (es) |
| KR (2) | KR20250035597A (es) |
| CN (4) | CN111848586B (es) |
| AR (1) | AR106138A1 (es) |
| AU (1) | AU2016328764B2 (es) |
| BR (1) | BR112018005833B1 (es) |
| CA (1) | CA2995430C (es) |
| DK (1) | DK3353168T3 (es) |
| ES (1) | ES2956642T3 (es) |
| MX (1) | MX375724B (es) |
| PT (1) | PT3353168T (es) |
| RU (1) | RU2760359C2 (es) |
| TW (1) | TWI740843B (es) |
| WO (1) | WO2017050938A1 (es) |
| ZA (1) | ZA201800782B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3353168T (pt) * | 2015-09-25 | 2023-09-20 | Dizal Jiangsu Pharmaceutical Co Ltd | Compostos e métodos para inibir jak |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| JOP20190174B1 (ar) * | 2017-01-17 | 2023-09-17 | Astrazeneca Ab | مثبطات jak1 انتقائية |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| MY209356A (en) * | 2018-07-18 | 2025-07-03 | Astrazeneca Ab | A xinafoate salt of a jak inhibiting compound |
| KR102669660B1 (ko) * | 2018-09-21 | 2024-05-27 | 상하이 엔노바바이오 파마슈티컬스 씨오 엘티디. | 키나아제 억제 활성을 가진 방향족 헤테로고리 화합물 |
| KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2021012749A (es) * | 2019-04-19 | 2021-11-18 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidor selectivo de la jak1 cinasa. |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN111961037B (zh) * | 2020-09-17 | 2021-09-21 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的药物化合物 |
| CN114269736B (zh) * | 2020-11-26 | 2024-02-02 | 科辉智药(深圳)新药研究中心有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| EP4297873A1 (en) * | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| MX2023010642A (es) * | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| WO2025230951A1 (en) * | 2024-04-29 | 2025-11-06 | Icahn School Of Medicine At Mount Sinai | Method of treating adenoid cystic carcinoma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005027825D1 (de) * | 2004-03-30 | 2011-06-16 | Vertex Pharma | Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| TW200800963A (en) | 2005-10-28 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| PT2091918E (pt) * | 2006-12-08 | 2014-11-24 | Irm Llc | Compostos e composições como inibidores de proteína cinase |
| JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| WO2010135650A1 (en) * | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2012030910A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| WO2012062704A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EA026201B1 (ru) * | 2010-11-19 | 2017-03-31 | Инсайт Холдингс Корпорейшн | Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak |
| US20140045908A1 (en) * | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| CA2839767A1 (en) * | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| EP3459565A1 (en) | 2012-03-29 | 2019-03-27 | The Trustees of Columbia University in the City of New York | Methods for treating hair loss disorders |
| PT3353168T (pt) * | 2015-09-25 | 2023-09-20 | Dizal Jiangsu Pharmaceutical Co Ltd | Compostos e métodos para inibir jak |
-
2016
- 2016-09-22 PT PT167700319T patent/PT3353168T/pt unknown
- 2016-09-22 AU AU2016328764A patent/AU2016328764B2/en active Active
- 2016-09-22 CA CA2995430A patent/CA2995430C/en active Active
- 2016-09-22 CN CN202010626114.2A patent/CN111848586B/zh active Active
- 2016-09-22 BR BR112018005833-5A patent/BR112018005833B1/pt active IP Right Grant
- 2016-09-22 KR KR1020257006096A patent/KR20250035597A/ko active Pending
- 2016-09-22 RU RU2018112993A patent/RU2760359C2/ru active
- 2016-09-22 EP EP16770031.9A patent/EP3353168B1/en active Active
- 2016-09-22 WO PCT/EP2016/072616 patent/WO2017050938A1/en not_active Ceased
- 2016-09-22 CN CN201680055491.7A patent/CN108368091B/zh active Active
- 2016-09-22 US US15/272,554 patent/US9714236B2/en active Active
- 2016-09-22 KR KR1020187008186A patent/KR102774784B1/ko active Active
- 2016-09-22 JP JP2018535238A patent/JP6767491B2/ja active Active
- 2016-09-22 DK DK16770031.9T patent/DK3353168T3/da active
- 2016-09-22 ES ES16770031T patent/ES2956642T3/es active Active
- 2016-09-22 MX MX2018003590A patent/MX375724B/es active IP Right Grant
- 2016-09-22 CN CN202010629286.5A patent/CN111646980B/zh active Active
- 2016-09-22 EP EP23150992.8A patent/EP4219482A1/en active Pending
- 2016-09-22 CN CN202010629290.1A patent/CN111606893B/zh active Active
- 2016-09-23 TW TW105130891A patent/TWI740843B/zh active
- 2016-09-23 AR ARP160102919A patent/AR106138A1/es active IP Right Grant
-
2017
- 2017-05-22 US US15/601,324 patent/US10167276B2/en active Active
-
2018
- 2018-02-06 ZA ZA2018/00782A patent/ZA201800782B/en unknown
- 2018-11-20 US US16/196,038 patent/US10654835B2/en active Active
-
2020
- 2020-04-28 US US16/860,169 patent/US11247983B2/en active Active
-
2021
- 2021-12-28 US US17/563,913 patent/US12319670B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106138A1 (es) | Compuestos y métodos para inhibir jak | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR102977A1 (es) | Inhibidores de erk | |
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR110405A1 (es) | Compuestos | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR090836A1 (es) | Derivados de benzamida | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR098522A1 (es) | Compuesto de triazolo-piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |